| 0.9888 -0.151 (-13.26%) | 03-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.22 |
1-year : | 1.44 |
| Resists | First : | 1.05 |
Second : | 1.24 |
| Pivot price | 0.95  |
|||
| Supports | First : | 0.74 |
Second : | 0.61 |
| MAs | MA(5) : | 1.01 |
MA(20) : | 0.91 |
| MA(100) : | 1.42 |
MA(250) : | 2.79 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61.1 |
D(3) : | 56.2 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 13.22 | Low : | 0.74 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TIVC ] has closed below upper band by 36.6%. Bollinger Bands are 56.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.03 - 1.03 | 1.03 - 1.03 |
| Low: | 0.88 - 0.88 | 0.88 - 0.89 |
| Close: | 0.98 - 0.99 | 0.99 - 1 |
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Fri, 27 Mar 2026
Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome - National Today
Thu, 26 Mar 2026
Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome - Bitget
Thu, 26 Mar 2026
U.S.-funded Tivic study targets deadly gut damage after radiation - Stock Titan
Thu, 26 Mar 2026
Tivic Health Systems, Inc. Relocates Headquarters to San Antonio, Texas and Discontinues ClearUP Operations - Minichart
Wed, 25 Mar 2026
Tivic Health outlines $20B oncology market opportunity following strategic transformation - MSN
Wed, 25 Mar 2026
Earnings call transcript: Tivic Health pivots to biopharma focus in Q4 2025 By Investing.com - Investing.com South Africa
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1.53e+006 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 79 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.4e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 700.6 % |
| Return on Equity (ttm) | -96.2 % |
| Qtrly Rev. Growth | 482000 % |
| Gross Profit (p.s.) | 7.91 |
| Sales Per Share | -88.65 |
| EBITDA (p.s.) | -139303 |
| Qtrly Earnings Growth | -8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.59 |
| Dividend | 0 |
| Forward Dividend | 47050 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|